(Q46934509)

English

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study

scientific article published in January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

cancer metastasis

1 reference

based on heuristic

inferred from title

Josep Tabernero Caturla

11

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Eduardo Díaz-Rubio

14

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

author name string

Albert Abad

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Bartomeu Massuti

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Antonio Antón

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Maria Eugenia Vega

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Ana L Yuste

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Eugenio Marcuello

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

José Luis Manzano

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Vicente Alonso

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Alfredo Carrato

9

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Mercedes Martinez-Villacampa

10

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Enrique Aranda

12

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Fernando Rivera

13

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Spanish Cooperative Group for Digestive Tumor Therapy

15

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

publication date

1 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Acta Oncologica

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

47

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

286-292

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study

1 reference

https://api.crossref.org/works/10.1080%2F02841860701630259

21 January 2018

Identifiers

10.1080/02841860701630259

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17957505

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46934509&oldid=2138516726"